Using baclofen to treat anxiety and alcohol use disorder
Investigating the Efficacy of Baclofen in Patients with Alcohol Use Disorder (AUD) and Comorbid Anxiety Symptoms
NA · Universitair Ziekenhuis Brussel · NCT06835907
This study is testing if baclofen can help people with alcohol use disorder who also have anxiety feel better and drink less.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 58 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel (other) |
| Locations | 1 site (Jette, Brussels Capital) |
| Trial ID | NCT06835907 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of baclofen in treating alcohol use disorder (AUD) among patients, particularly focusing on those with varying levels of anxiety symptoms. Participants who are already on baclofen will complete questionnaires over a six-week period to assess their drinking behaviors, anxiety levels, and other related factors. The study aims to determine if higher anxiety symptoms correlate with fewer abstinent days and other treatment outcomes. By analyzing these responses, the trial seeks to provide insights into the relationship between anxiety and alcohol use in patients receiving baclofen.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with alcohol use disorder who are already receiving baclofen and have a desire for alcohol abstinence.
Not a fit: Patients with concurrent substance use disorders or significant psychiatric illnesses requiring pharmacotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic approach for treating alcohol use disorder, especially in patients with anxiety.
How similar studies have performed: While the use of baclofen for AUD has been explored, this specific focus on anxiety symptoms in conjunction with AUD treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meeting DSM-5 criteria for AUD * Able to understand and provide written consent * Already receiving baclofen or started with baclofen at start of hospitalization * Therapeutic desire towards alcohol abstinence Exclusion Criteria: * Concurrent substance use disorder other than nicotine or cannabis * Clinically significant psychiatric illness that requires pharmacotherapy, unless stable and no changes in medication has been made in the last 30 days * Clinically significant medical diseases that may pose a risk to continuing baclofen use * Pregnant or currently breastfeeding women
Where this trial is running
Jette, Brussels Capital
- Universitair Ziekenhuis Brussel — Jette, Brussels Capital, Belgium (RECRUITING)
Study contacts
- Principal investigator: Cleo L Crunelle — Universitair Ziekenhuis Brussel
- Study coordinator: Cleo L Crunelle
- Email: cleo.crunelle@vub.be
- Phone: +32 477 77 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alcohol Use Disorder, Alcohol use disorder, Baclofen, Anxiety